Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

What's the purpose of this trial?

An open-label, multicenter, dose escalation study to evaluate the safety, tolerability and PK/pharmacodynamics of AO-176 in adults with relapsed/refractory multiple myeloma whose disease has progressed following at least 3 prior systemic lines of treatment and must have progressed on the final line of therapy received before being considered for this study. The study will be conducted in 2 phases; Phase 1 is an ascending-dose study of AO-176 monotherapy utilizing the classic 3+3 design, with enrollment of 3 patients per cohort and expansion of the cohort in the event of a dose-limiting toxicity (DLT). Following the dose escalation portion and determination of the monotherapy recommended phase 2 dose (RP2D), an ascending dose escalation study of AO-176 and dexamethasone combined with bortezomib will be evaluated utilizing the same 3+3 dose escalation design. Phase 2 will evaluate the clinical activity of AO-176 plus dexamethasone and bortezomib at the RP2D as determined in Phase 1 Part 2.

This trial has temporarily put patient recruitment on hold.

Additional Trial Information

Phase 1/2

Enrollment: 157 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Mayo Clinic (Arizona)

Phoenix, AZ

Recruitment on Hold


Mayo Clinic (Jacksonville)

Jacksonville, FL

Recruitment on Hold


Winship Cancer Institute of Emory University

Atlanta, GA

Recruitment on Hold


Beth Israel Deaconess Medical Center

Boston, MA

Not Yet Accepting

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting


Mayo Clinic (Rochester)

Rochester, MN

Recruitment on Hold


Swedish - Cherry Hill Campus Cherry Hill Campus

Seattle, WA

Not Yet Accepting


Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

Recruitment on Hold

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Arch Oncology to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors